Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 4
2015 1
2016 1
2017 1
2018 2
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS. Bar-Or A, et al. Among authors: Grove RA. Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25. Neurology. 2018. PMID: 29695594 Free PMC article. Clinical Trial.
Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Snedecor SJ, et al. Among authors: Grove R. BMC Infect Dis. 2019 May 30;19(1):484. doi: 10.1186/s12879-019-3975-6. BMC Infect Dis. 2019. PMID: 31146698 Free PMC article.
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V; BEL115123 Study Group. Hewett K, et al. Among authors: Grove RA. Neurology. 2018 Apr 17;90(16):e1425-e1434. doi: 10.1212/WNL.0000000000005323. Epub 2018 Mar 21. Neurology. 2018. PMID: 29661905 Free PMC article. Clinical Trial.
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
Schwartzbach CJ, Grove RA, Brown R, Tompson D, Then Bergh F, Arnold DL. Schwartzbach CJ, et al. Among authors: Grove RA. J Neurol. 2017 Feb;264(2):304-315. doi: 10.1007/s00415-016-8341-7. Epub 2016 Nov 25. J Neurol. 2017. PMID: 27888416 Free PMC article. Clinical Trial.
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.
Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA. Jarskog LF, et al. Among authors: Grove RA. Schizophr Res. 2015 May;164(1-3):136-42. doi: 10.1016/j.schres.2015.01.041. Epub 2015 Feb 24. Schizophr Res. 2015. PMID: 25728831 Clinical Trial.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua P, Yousry T, Macmanus D, Montalban X. Miller DH, et al. Among authors: Grove R. Lancet Neurol. 2012 Feb;11(2):131-9. doi: 10.1016/S1474-4422(11)70299-X. Epub 2012 Jan 5. Lancet Neurol. 2012. PMID: 22226929 Clinical Trial.
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP. Grove RA, et al. Curr Alzheimer Res. 2014 Jan;11(1):47-58. doi: 10.2174/1567205010666131212110148. Curr Alzheimer Res. 2014. PMID: 24359500 Clinical Trial.
12 results
Jump to page
Feedback